Danish manufacturer of weight-loss and diabetes drugs under pressure from US rival Eli Lilly Business live – latest newsThe Danish maker of the weight-loss drug Wegovy and diabetes drug Ozempic is to cut 9,000 jobs as it issued a profit warning amid fierce competition from its US rival Eli Lilly.Novo Nordisk’s decision to cut 11% of its global workforce of 78,400 takes place as sales of Wegovy have slowed sharply as it has lost ground to Eli Lilly’s Mounjaro jabs, as well as cheaper versions by generic drugmakers, and the pharmaceutical sector faces the threat of targeted US tariffs. Continue reading...
Continua a leggere su "The Guardian"